Tubular \( \beta \)-catenin and FoxO3 interactions protect in chronic kidney disease

Stellar Nlandu-Khodo, …, Ethan Lee, Leslie S. Gewin

*JCI Insight.* 2020;5(10):e135454. [https://doi.org/10.1172/jci.insight.135454](https://doi.org/10.1172/jci.insight.135454).

**Graphical abstract**

Find the latest version:

[https://jci.me/135454/pdf](https://jci.me/135454/pdf)
Tubular β-catenin and FoxO3 interactions protect in chronic kidney disease

Stellor Nlandu-Khodo,1,2 Yosuke Osaki,1 Lauren Scarfe,1 Haichun Yang,3 Melanie Phillips-Mignemi,1 Jane Tonello,1 Kenyi Saito-Diaz,4 Surekha Neelisetty,1 Alla Ivanova,1 Tessa Huffstater,5 Robert McMahon,1 M. Mark Taketo,4 Mark deCaestecker,1 Balakuntalam Kasinath,7 Raymond C. Harris,1,8,9 Ethan Lee,4 and Leslie S. Gewin1,4,9

1Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, Tennessee, USA. 2Institute of Physiology, University of Zurich, Zurich, Switzerland. 3Department of Pathology, Microbiology and Immunology, VUMC, Nashville, Tennessee, USA. 4Department of Cell and Developmental Biology and Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, USA. 5Division of Experimental Therapeutics, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 6Department of Medicine, Long School of Medicine, University of Texas Health San Antonio, San Antonio, Texas, USA. 7Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, USA. 8Department of Medicine, Veterans Affairs Hospital, Tennessee Valley Healthcare System, Nashville, Tennessee, USA.

Introduction

Chronic kidney disease (CKD) affects nearly 15% of the American population (1) with a global prevalence of more than 11% (2) and presents a high economic burden as well as increased cardiovascular morbidity and mortality. Acute kidney injury (AKI), commonly caused by sepsis, drugs, and ischemia, often appears to resolve by measures of renal function but independently increases the risk of CKD development and progression (3). AKI conversion to CKD is a complex process involving many cell types, but the proximal tubule is arguably the central player because it is the target of acute injury. Others have shown that isolated injury to the proximal tubule, if severe enough or repetitive, is sufficient to cause tubular atrophy and renal fibrosis, the hallmark of CKD (4, 5). In response to injury, the proximal tubule undergoes changes in cell cycle, differentiation, and metabolism, and these proximal tubule–specific responses may determine whether the kidney undergoes successful repair or progresses to CKD after injury.

The injured proximal tubule recapitulates expression of many growth factors that are involved in renal development. The Wnt/β-catenin pathway is critical for renal development but quiescent in the uninjured adult kidney with the exception of the renal medulla (6–8). β-Catenin signaling is protective in acute kidney injury (AKI) through actions on the proximal tubule, but the current dogma is that Wnt/β-catenin signaling promotes fibrosis and development of chronic kidney disease (CKD). As the role of proximal tubular β-catenin signaling in CKD remains unclear, we genetically stabilized (i.e., activated) β-catenin specifically in murine proximal tubules. Mice with increased tubular β-catenin signaling were protected in 2 murine models of AKI to CKD progression. Oxidative stress, a common feature of CKD, reduced the conventional T cell factor/lymphoid enhancer factor–dependent β-catenin signaling and augmented FoxO3-dependent activity in proximal tubule cells in vitro and in vivo. The protective effect of proximal tubular β-catenin in renal injury required the presence of FoxO3 in vivo. Furthermore, we identified cystathionine γ-lyase as a potentially novel transcriptional target of β-catenin/FoxO3 interactions in the proximal tubule. Thus, our studies overturned the conventional dogma about β-catenin signaling and CKD by showing a protective effect of proximal tubule β-catenin in CKD and identified a potentially new transcriptional target of β-catenin/FoxO3 signaling that has therapeutic potential for CKD.

The Wnt/β-catenin signaling pathway plays an important role in renal development and is reexpressed in the injured kidney and other organs. β-Catenin signaling is protective in acute kidney injury (AKI) through actions on the proximal tubule, but the current dogma is that Wnt/β-catenin signaling promotes fibrosis and development of chronic kidney disease (CKD). As the role of proximal tubular β-catenin signaling in CKD remains unclear, we genetically stabilized (i.e., activated) β-catenin specifically in murine proximal tubules. Mice with increased tubular β-catenin signaling were protected in 2 murine models of AKI to CKD progression. Oxidative stress, a common feature of CKD, reduced the conventional T cell factor/lymphoid enhancer factor–dependent β-catenin signaling and augmented FoxO3-dependent activity in proximal tubule cells in vitro and in vivo. The protective effect of proximal tubular β-catenin in renal injury required the presence of FoxO3 in vivo. Furthermore, we identified cystathionine γ-lyase as a potentially novel transcriptional target of β-catenin/FoxO3 interactions in the proximal tubule. Thus, our studies overturned the conventional dogma about β-catenin signaling and CKD by showing a protective effect of proximal tubule β-catenin in CKD and identified a potentially new transcriptional target of β-catenin/FoxO3 signaling that has therapeutic potential for CKD.
kinase 1. When 1 of the 19 Wnt ligands binds to the frizzled receptor and the LDL-receptor-related protein 5/6 coreceptors, β-catenin escapes degradation and accumulates in the nucleus (9). Nuclear β-catenin, in complex with T cell factor/lymphoid enhancer factor (TCF/LEF), activates Wnt target genes to modulate cellular responses, such as proliferation, survival, and differentiation.

Wnt/β-catenin signaling increases after renal injury, particularly in the renal tubules (10–12). Several studies show that β-catenin activity is protective in AKI, primarily by either reducing apoptosis or enhancing proliferation in the proximal tubules (11, 13–15). By contrast, studies that overexpress Wnt ligands or block β-catenin signaling systemically suggest that this growth factor promotes fibrosis in CKD (16–19). In addition, activating Wnt/β-catenin in renal tubule cells in vitro causes dedifferentiation (20), and persistently dedifferentiated epithelial cells play an important role in the AKI-to-CKD transition (21). However, no studies to date have shown how augmenting β-catenin signaling exclusively in the proximal tubule, a key target of renal injury, affects CKD. To address this, we conditionally stabilized (i.e., activated) β-catenin in the proximal tubules after birth and used 2 models of AKI to CKD. Contrary to the conventional dogma that β-catenin promotes chronic injury and fibrosis, mice with increased β-catenin activity specifically in the proximal tubule were protected from kidney fibrosis and epithelial injury. This protection was dependent upon the expression of the transcription factor FoxO3, which can mediate stress responses such as antioxidant production, cell cycle arrest, and altered cell survival (22). Furthermore, we identified potentially novel downstream transcriptional targets of β-catenin and FoxO3 interactions that may inform new therapies for CKD.

Results

Increased β-catenin activity in proximal tubules is protective in AKI to CKD models. We generated mice with increased β-catenin activity in the proximal tubule by crossing Ggt-Cre mice (23) with Ctnnb1^flox/flox mice in which the phosphorylation site targeting β-catenin for degradation is floxed (24). Nuclear β-catenin protein expression (i.e., transcriptionally active β-catenin) from renal cortices was increased in the Ggt-Cre Ctnnb1^flox/flox mice, consistent with recombination (Supplemental Figure 1, A and B; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.135454DS1). In addition, transcripts of Axin2, a well-characterized endogenous readout for β-catenin and TCF/LEF signaling (25), were increased 10-fold compared with floxed WT mice (Supplemental Figure 1C). Proximal tubule localization of β-catenin activity was confirmed by crossing the mice with Topflash reporter (Tcf/Lef:H2B-GFP) mice (26) and containing with lotus tetragonolobus (LTL), a lectin specific for proximal tubules (Supplemental Figure 1D). No differences between the uninjured Ggt-Cre Ctnnb1^flox/flox and floxed WT mice were noted (Figure 1A). The mice were injured with aristolochic acid, a cause of acute to chronic kidney injury that targets the proximal tubule in humans and causes cell death acutely but later results in interstitial fibrosis (27, 28). Six weeks after AAN, tubular injury was significantly attenuated in the Ggt-Cre Ctnnb1^flox/flox mice, as measured by tubular injury scores (see Methods) and expression of KIM-1 (Haver1), an indicator of proximal tubule injury, compared with floxed littermates (Figure 1, A–C). Tubulointerstitial fibrosis was also reduced in the mice with conditional β-catenin stabilization according to picrosirius red staining as well as collagen I transcripts (Figure 1, D–F), and renal function, measured by blood urea nitrogen (BUN), was better preserved (Figure 1G).

We then subjected our mice to another AKI to CKD model induced by unilateral ischemia/reperfusion injury (IRI) followed by contralateral nephrectomy 8 days later, and the mice were sacrificed 4 weeks after the ischemic event. Similar to the AAN model, the Ggt-Cre Ctnnb1^flox/flox mice had significantly reduced KIM-1 (Haver1) and BUN compared with floxed littermates (Figure 1, H–J). To further characterize proximal tubule injury, we stained LTL, a lectin expressed on the brush border specifically of differentiated proximal tubules (29). There was significantly increased expression in the Ggt-Cre Ctnnb1^flox/flox compared with floxed controls after IRI, indicating less epithelial dedifferentiation after injury (Figure 1, K and L). There was a trend toward reduction in collagen transcripts in the Ggt-Cre Ctnnb1^flox/flox mice, but it did not reach statistical significance (P = 0.06, Figure 1M). Taken together, these data indicate that increasing β-catenin signaling in proximal tubules protects against tubule injury and preserves function in 2 models of AKI to CKD.

Augmenting β-catenin signaling protects against tubule epithelial apoptosis. Given the tubular protection in injured Ggt-Cre Ctnnb1^flox/flox mice, reflected by decreased KIM-1 levels and BUN after both AAN and IRI, we investigated how β-catenin signaling affected epithelial apoptosis. There were fewer TUNEL+ cortical tubule cells, a measure of apoptosis/necrosis, in AAN-injured mice with β-catenin stabilized in proximal tubules compared with floxed controls (Figure 2, A and B). We used conditionally immortalized proximal tubule (PT) cells previously isolated and characterized (30) and exposed them to AA for 7 days in vitro to mimic
Figure 1. Increased β-catenin signaling in proximal tubules protects against AKI to CKD injury. 

(A) H&E sections of Ggt-Cre Ctnnb1<sup>flox<sup>fl</sup> mice and floxed controls without injury as well as 6 weeks after aristolochic acid nephropathy (AAN). Scale bars: 50 μm. 

(B) Injury was scored by colleagues who did not know the identity of the genotype (see Methods for scoring system). 

(C) KIM-1 (Havcr1) levels were measured by quantitative PCR, normalized to Gapdh, in cortical tissue from both uninjured and aristolochic acid–treated mice. 

(D and E) Picrosirius red (Sirius Red) staining measured collagen (red staining) and was quantified using ImageJ (NIH). Scale bar: 50 μm. 

(F) Collagen I (Col1a1) transcripts were measured by quantitative PCR (qPCR), normalized to Gapdh, from renal cortices 6 weeks after AAN. 

(G) Blood urea nitrogen (BUN) was measured from mice either uninjured or 6 weeks after AAN. 

(H) H&E from Ggt-Cre Ctnnb1<sup>flox<sup>fl</sup> mice and floxed controls injured by IRI and sacrificed 4 weeks later (see Methods for details). Scale bar: 50 μm for original magnification ×200 and 50 μm for ×400. 

(I) KIM-1 (Havcr1) expression in renal tissue after IRI injury and (J) BUN levels were measured at the time of sacrifice (4 weeks after IRI). Staining for lotus tetragonolobus (LTL) conjugated to GFP was done. Scale bar: 100 μm for original magnification ×200 and 50 μm for ×100 (K) and quantified by ImageJ (L). 

(M) Collagen (Col1a1) levels were measured by qPCR from renal tissue 4 weeks after IRI. For all qPCR studies after IRI, the inner medulla was dissected away and discarded. Statistical analyses were done using the Student’s t test with *P < 0.05, **P < 0.01, and ***P < 0.001. For the AAN injury, 1 Ctnnb1<sup>flox<sup>fl</sup> mouse died before the study’s completion, and for the IRI model, 1 mouse per genotype died prematurely.
chronic exposure. The AA-induced apoptosis, detected by cleaved caspase-3, was significantly reduced by treatment with a GSK-3 inhibitor (BIO), which augments β-catenin signaling (Figure 2, C and D). Because GSK-3 inhibitors can have β-catenin–independent effects, we also treated PT cells with the Wnt3a ligand, upregulated in renal injury (31), and saw a significant reduction in AA-induced apoptosis (Figure 2, E and F). Thus, increasing β-catenin signaling in PT cells reduced apoptosis in vivo and in vitro after AA exposure.

Oxidative stress alters β-catenin–dependent transcriptional activity. Others have reported that oxidative stress changes β-catenin’s nuclear binding partners from TCF/LEF- to FoxO-dependent transcription, but this has not been investigated in tubular injury (32). The FoxO transcription factors play a critical role in regulating oxidative stress, proliferation, and cell survival, so this transcriptional switch may explain the protective effect of β-catenin in injured epithelia. In oxidative stress, FoxO1/3 transcription factors are thought to competitively inhibit TCF/LEF binding to β-catenin and, hence, TCF/LEF-dependent transcription (33, 34). As expected, Wnt3a ligand dose-dependently increased the expression of axin2, but the presence of oxidative stress (100 μM H₂O₂) greatly attenuated the Wnt3a-dependent axin2 expression (Figure 3A). To further investigate the effect of oxidative stress on β-catenin– and TCF/LEF-dependent activity, we stably transfected our PT cells with the Topflash reporter, a direct indicator of TCF/LEF-dependent β-catenin signaling (35). The addition of Wnt3a augmented the luminescent signal but was attenuated in the presence of oxidative stress (H₂O₂) (Figure 3B). These assays both show that oxidative stress reduces TCF/LEF-dependent β-catenin activity in PT cells.

We then asked whether the oxidative stress–dependent decrease in LEF/TCF-dependent β-catenin signaling was accompanied by increased FoxO activity. We showed that AA increases oxidative stress in PT cells in vitro with nitrotyrosine immunoblots (Figure 3C). The presence of AA and the Wnt3a ligand synergistically increased nuclear FoxO1 and FoxO3, with the latter being more abundant in PT cells (Figure 3, D and E). Nuclear FoxO1/3 is thought to represent active FoxO1/3, and the presence of both AA and Wnt3a was required to significantly raise FoxO activity. To determine whether oxidative stress induces FoxO3 nuclear binding to β-catenin, we performed coimmunoprecipitation studies of nuclear isolates with or without H₂O₂ (oxidative stress) and Wnt3a. Indeed, β-catenin and FoxO3 form a complex in the nucleus but only in the presence of both oxidative stress and Wnt3a (Figure 3, F and G). Furthermore, treatment with Wnt3a increased nuclear β-catenin as expected, and oxidative stress did not enhance nuclear β-catenin, suggesting that the increased binding of nuclear FoxO3 with β-catenin under oxidative stress was not due to increased nuclear β-catenin expression (Figure 3, F and H). In summary, oxidative stress reduces β-catenin–dependent LFC/TCF transcriptional responses while increasing FoxO3 activity and potentially transcriptional binding between β-catenin and FoxO3.

We then investigated how these oxidative stress–dependent alterations in TCF/LEF and FoxO3 activity affect the PT’s response to AA-induced injury. We knocked down FoxO3 using siRNA (Figure 4A) and showed that reduced FoxO3 potentiated apoptosis in PT cells treated with AA (Figure 4, B and C). To block β-catenin/TCF/LEF interactions, we used ICG-001, a small-molecule inhibitor of β-catenin/TCF signaling widely used to block these interactions (36). AA-induced apoptosis in PT cells was significantly reduced with the addition of ICG-001 (Figure 4, D and E). Taken together, these data suggest that switching β-catenin away from TCF/LEF-dependent and toward FoxO3-dependent signaling protects PT cells from AA-induced apoptosis.

Injured PTs with β-catenin stabilized have increased FoxO3 expression, which is necessary for a protective effect. We wanted to verify that this β-catenin–dependent increased FoxO3 activity in oxidative stress was present in vivo. AA induces oxidative stress, and the Ggt-Cre Ctnnb1ex3/+/ mice had more LTL+ tubules (i.e., PTs) with FoxO3 staining after AAN compared with floxed controls (Figure 5, A and B). However, consistent with the greater injury sustained and higher KIM-1 (Haver) expression, the floxed control mice had fewer LTL+ tubules because this lectin is expressed on the brush border, which is lost in severe injury. Therefore, we also quantified the total number of FoxO3+ cortical tubules, which was significantly higher in the Ggt-Cre Ctnnb1ex3/+/ mice (Figure 5C). We confirmed that most FoxO3 staining was nuclear (i.e., active FoxO3) by merging FoxO3 with DAPI (Figure 5D).

We next investigated whether this augmented FoxO3 activity was required for the β-catenin–dependent protective effect in PT cells in vivo. We crossed the Ggt-Cre Ctnnb1ex3/+/ with Foxo3fl/fl mice to generate double-transgenic mice with PT-specific increased β-catenin activity and deleted FoxO3 (Ggt-Cre Ctnnb1ex3/+. Foxo3fl/fl). Recombination was verified by measuring Axin2 transcripts in renal cortices and FoxO3 from primary cortical tubule cells of injured mice (Supplemental Figure 2, A and B). After AAN, robust injury was induced in both the double conditional knockout and the floxed controls, but
the BUN and KIM-1 levels were not significantly different at 6 weeks after injury between the 2 genotypes (Figure 5, E–G). Furthermore, measurements of fibrosis (collagen I transcripts by qPCR and picrosirius red staining) showed a nonsignificant trend toward the double–conditional knockout mouse having more rather than less fibrosis (Figure 5, H–J). In summary, the protective effect noted previously in mice with PT-specific β-catenin stabilization requires the presence of FoxO3.

Cystathionine γ-lyase is a potentially novel target of β-catenin/FoxO3. Most of β-catenin's downstream effects have been described in the context of β-catenin's interactions with TCF/LEF without regard for oxidative stress's impact on β-catenin's downstream transcriptional targets. The β-catenin/FoxO complex was shown to be protective in inflammatory cells in the context of TGF-β–induced injury (36), but the downstream targets mediating this protective effect were not identified. We used RNA-Seq to identify novel targets of β-catenin/FoxO in renal epithelial cells that may be mediating this protective effect in injury. PT cells were treated with scramble, Foxo1, or Foxo3 siRNA; β-catenin was activated with Wnt3a; and oxidative stress was induced with H2O2 (Figure 6A). There were no statistically significant differences in transcripts between scramble and Foxo1 siRNA, but 12 genes were suppressed and 7 augmented by Foxo3 siRNA (Table 1). Some of these FoxO3-regulated genes have been previously described as targets of β-catenin, such as Ctgf and Serpinel1 (37, 38). However, Cth, which codes for cystathionine γ-lyase (CSE), is, as far as we are aware, a novel target of β-catenin/FoxO3. CSE catalyzes the formation of hydrogen sulfide (H2S) and the antioxidant glutathione, and renoprotective roles for both CSE and H2S have been described (39–41).

We used qPCR to confirm reduction of Cth in Foxo3 siRNA–treated PT cells treated with Wnt3a but only in the presence of H2O2-induced oxidative stress (Figure 6B). In addition, a GSK-3 inhibitor augmented CSE protein expression in AA-treated PT cells (Figure 6, C and D). Knockdown of Cth exacerbated
AA-induced apoptosis, suggesting that this target is a potential mediator of epithelial β-catenin/FoxO3-dependent cytoprotection (Figure 6, E and F). We then assessed whether CSE expression was altered in injured mice with β-catenin stabilized in the PT. CSE was markedly upregulated in cortical lysates of AAN-injured Ggt-Cre Ctnnb1ex3fl/fl mice compared with floxed controls (Figure 7, A and B). Staining for CSE revealed its distribution to be primarily in cortical tubules, consistent with PTs, in uninjured mice (Figure 7C). The levels of Cth transcripts also decreased in both genotypes after chronic injury, but levels in the AAN-injured Ggt-Cre Ctnnb1ex3fl/fl mice were significantly higher compared with those of the injured floxed
littermates (Figure 7D). The augmented CSE expression noted in conditionally β-catenin–stabilized mice (Figure 7A) was erased when FoxO3 was also deleted (Figure 7E). In summary, CSE was identified as a novel target of β-catenin and FoxO3 in oxidative stress, knockdown of Cth worsened AA-induced apoptosis in vitro, and injured mice with increased tubular β-catenin activity had increased CSE protein expression and Cth transcripts compared with floxed controls.

Discussion
The PT plays a critical role in renal injury by either facilitating repair or mediating AKI progression to CKD, and growth factors play an important role in both processes. The role of β-catenin signaling in proximal tubular responses to chronic injury had not been well delineated. The current studies reveal a potentially novel protective pathway in the progression of AKI to CKD by showing (a) cell-autonomous β-catenin signaling in the PT protects against fibrosis and preserves renal function in 2 AKI to CKD models, (b) proximal tubular β-catenin activity enhances active (i.e., nuclear) FoxO3 in oxidative stress in vitro, (c) the protective effect of proximal tubular β-catenin in vivo requires the presence of FoxO3, and (d) CSE is a novel downstream target of β-catenin/FoxO3 in renal tubules and may mediate some of the antiapoptotic and antioxidant actions of these transcription factors.

Our finding that proximal tubular β-catenin protects against the development of CKD may be surprising given the many reports of β-catenin as a profibrotic factor in chronic injury. This paradigm of β-catenin as a mediator of fibrosis in CKD is largely based upon studies in which Wnt ligands are overexpressed or systemic inhibitors are used. Because Wnt ligands are soluble, even though they may be produced by tubules, they clearly have potent profibrotic actions on surrounding fibroblasts and pericytes (17, 42, 43). The other caveat about genetic overexpression of Wnts, or other ligands, is that the levels may be higher than those in pathophysiological states. Studies using systemic Wnt/β-catenin inhibitors are useful for therapeutic investigation but do not elucidate the cell-specific roles of this pathway in injury. Several studies have used ICG-001 as a Wnt/β-catenin inhibitor, but this compound actually blocks the NH2 terminus of cyclic AMP response element–binding protein (CBP), which inhibits β-catenin/TCF–mediated transcription (44). As recently shown in immune cells, ICG-001 does not completely block all β-catenin signaling but rather β-catenin/TCF–dependent signaling (36). Another concern with ICG-001 is that it can inhibit signaling pathways other than β-catenin that are dependent upon binding to the amino terminus of CBP.

Stabilizing β-catenin in P Ts using Ggt-Cre was beneficial in 2 models of AKI to CKD progression. One question about this genetic model is whether the deletion of exon 3 negatively affects β-catenin binding to TCF/LEF or artificially augments binding to FoxO3. In Supplemental Figure 1, we show that β-catenin signaling with TCF/LEF is augmented in the conditional β-catenin–stabilized mouse using the Topflash reporter mice and Axin2 expression, both of which depend upon TCF/LEF binding, without renal injury.
(i.e., oxidative stress), indicating that β-catenin binding to TCF/LEF is intact. Although we cannot definitively rule out the possibility that exon 3 deletion enhances β-catenin binding to FoxO3, the location of exon 3 (NH₂ terminal region of β-catenin) (24, 45) is distinct from the central armadillo repeat region of β-catenin, which is the binding site of FoxO3 (32). In addition, our in vitro studies show that β-catenin

Figure 5. FoxO3 expression is increased in PTs with β-catenin stabilized and is required for the protective effect of β-catenin in PTs in AAN. (A) FoxO3 (red) and LTL (green), a marker for PT cells, staining on frozen sections at 6 weeks after AAN with quantification of FoxO3+ LTL+ tubule cells (B) and FoxO3+ cortical tubule cells (C) per high-power field, original magnification, ×400. (D) FoxO3 staining (red) merged with DAPI (blue) staining to show nuclear localization of FoxO3. (E) H&E sections of mice with β-catenin stabilized and FoxO3 deleted from the PT (Ggt-Cre Ctnnb1ex3fl/fl Foxo3fl/fl) and floxed control mice both uninjured and 6 weeks after AAN. (F) BUN of mice uninjured and 6 weeks after AAN is shown as well as KIM-1 (Havcr1) and collagen I (Col1a1) transcript levels by qPCR after normalization to Gapdh (G and H). Picosirius red staining done on the mice 6 weeks after AAN (I) with quantification by ImageJ (J). Scale bar: 50 μm (black bar in original magnification ×400 and white bar in insets). In all graphs, Student’s t test was used to compare 2 sets of data (uninjured mice shown as controls but not included in statistical analyses) with *P < 0.05. One mouse from each genotype died before the study was completed.
binding to FoxO3 is enhanced in oxidative stress independent of the exon 3 mutation. Thus, there is no evidence that the conditionally β-catenin–stabilized mouse has impaired TCF/LEF binding, and it is unlikely, though not impossible, that FoxO3 binding is altered by exon 3 deletion.

Mice with conditional β-catenin stabilization had less epithelial injury as evidenced by preserved BUN and lower KIM-1 levels in both the AA and IRI models. Furthermore, the conditionally stabilized mice had increased LTL expression after IRI, indicating more differentiated PTs with brush border intact (29). There was protection against fibrosis in the AA model in which collagen expression and sirius red staining were significantly attenuated, whereas there was only a nonsignificant trend toward improvement in collagen (P = 0.06) and sirius red (data not shown) in the IRI model. This is partly explained by the difference in injury severity because the AA-treated floxed control mice had higher BUN levels 6 weeks later than did the IRI floxed controls. Both injuries target the PTs, causing direct and chronic tubular injury, which can lead to progressive CKD. Injury to the PTs is sufficient to cause fibrosis (4), but this is likely an indirect effect caused by paracrine signaling from injured tubules to neighboring myofibroblasts. From these models, one may conclude that epithelial β-catenin plays a stronger role in tubular survival and renal function than in renal fibrosis.

The AA model causes acute proximal tubular injury, which then progresses to chronic tubule damage and interstitial fibrosis. Continued tubular apoptosis/necrosis was detected even 6 weeks after injury based upon TUNEL+ tubule cells. Thus, we used an AA in vitro model of cell death to further explore the mechanisms of chronic injury. Treating PT cells with AA for 7 days is longer than most in vitro apoptotic stimuli though not a perfect mimic of the in vivo environment. Both FoxO3 and CSE protected PT cells from apoptosis in this in vitro model of AA. The relationship between tubular apoptosis and fibrosis requires
further research, but several studies have linked ongoing epithelial cell death to CKD progression in both human and rodent injured kidneys (46–51). Others have reported that β-catenin signaling may promote epithelial survival in AKI, but the dogma has been that prolonged β-catenin signaling would be detrimental in the context of CKD. Our data indicate that β-catenin/FoxO3 interactions in oxidative stress promote epithelial survival, potentially through the novel target CSE.

To our knowledge, this is the first study to increase β-catenin signaling specifically in PT cells. Another group stabilized β-catenin in tubules using the Ksp-Cre mouse model, which targets distal tubules more than PTs (52). They used a protein overload model of injury and did not observe differences in fibrosis but did report augmented inflammation in the Ksp-Cre mice. The differences in responses may be due to different tubule compartments being targeted and/or different amounts of β-catenin signaling. The distal tubule is known to have greater basal β-catenin signaling (6), and it is possible that augmenting this pathway above a certain amount is deleterious. This idea of a dose-dependent response or therapeutic window has support in both the developing kidney and the podocyte, where too little or too much β-catenin signaling was detrimental (7, 53). Our RNA-Seq data revealed several mediators of inflammation (e.g., Ctgf, Ccl18, Foxj1, Adgrg1) that were suppressed with Foxo3 siRNA. Thus, at higher levels of β-catenin activity as might be seen in distal tubules, these inflammatory effects may outweigh any antiapoptotic or antioxidant beneficial effects.

Interactions between β-catenin and FoxO transcription factors have been studied in the context of diabetes, cancer, aging, and bone formation (54–56). The specific effects of β-catenin/FoxO interactions vary depending upon the microenvironment, and the downstream mediators of these effects have not been well characterized. To our knowledge, our group is the first to investigate how oxidative stress–dependent β-catenin and FoxO3 interactions affect epithelial injury. Recently, another group showed that giving mice recombinant TGF-β and the ICG-001 inhibitor in models of renal fibrosis led to greater regulatory T cell (Treg) differentiation and less inflammation (36). This phenotype was thought to be due to beneficial actions of β-catenin and FoxO1 in promoting Tregs, thus suggesting that these interactions may be beneficial in cells other than PTs. Consistent with our data, this same group showed that FoxO1 protected murine kidney tubular cells from TGF-β–induced profibrotic protein expression in vitro (57). Surprisingly, oxidative stress alone reduced nuclear β-catenin (Figure 3F). Others have published that H2O2 reduces β-catenin signaling in endothelial cells through impaired miRNA-154, which inhibits dickkopf-related protein 2, an inhibitor of Wnt/β-catenin signaling (58). However, more research is necessary to determine whether this mechanism applies to renal tubules.

Our data suggest that FoxO3 is necessary for proximal tubular β-catenin-mediated protection in chronic injury because the mice with β-catenin stabilized but lacking FoxO3 lost their protective effect. FoxO transcription factors are known to have effects on antioxidant production, cell survival/apoptosis, and cell cycle. Conflicting reports exist about how these biological responses are affected, and there are numerous posttranslational modifications that can alter FoxO activity, perhaps accounting for its diverse context-dependent effects. This raises the critical question of what the transcriptional targets are that mediate

<table>
<thead>
<tr>
<th>Genes suppressed by Foxo3 siRNA</th>
<th>Genes augmented by Foxo3 siRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ctgf</td>
<td>Aqp1</td>
</tr>
<tr>
<td>Aldh1a2</td>
<td>Aldh1a7</td>
</tr>
<tr>
<td>Gadd45g</td>
<td>Cd55</td>
</tr>
<tr>
<td>Cth</td>
<td>Olfm1</td>
</tr>
<tr>
<td>Oasl2</td>
<td>Plat</td>
</tr>
<tr>
<td>Ccl17</td>
<td>Ces2e</td>
</tr>
<tr>
<td>Adgrg1</td>
<td>Aldh1a1</td>
</tr>
<tr>
<td>Foxj1</td>
<td></td>
</tr>
<tr>
<td>Ifit1</td>
<td></td>
</tr>
<tr>
<td>Serpine1</td>
<td></td>
</tr>
<tr>
<td>Dhrs3</td>
<td></td>
</tr>
<tr>
<td>Col4a4</td>
<td></td>
</tr>
</tbody>
</table>
these β-catenin/FoxO–dependent responses in the chronically injured kidney. We identified under 20 genes that were either up- or downregulated in Foxo3-siRNA–treated PT cells under conditions of oxidative stress and β-catenin activation (Table 1). We focused on CSE since this enzyme can reduce injury of the kidney and other organs and has not, to our knowledge, been identified as a downstream target of β-catenin/FoxO3 (41, 59). It is possible that β-catenin/FoxO3 directly target a different gene, which then modulates Cth transcription. Our studies did not determine whether β-catenin/FoxO3 directly or indirectly upregulate Cth gene expression in oxidative stress.

CSE is 1 of 3 enzymes involved in H2S generation, and CSE expression has been localized to the PTs, consistent with our immunohistochemistry data (60). H2S, like nitric oxide and carbon monoxide, is a gasotransmitter that is toxic at high doses, but at lower doses it acts as a signaling molecule to regulate biological processes, such as vascular tone and inflammation. Augmentation of H2S, generally from exogenous Na2S or NaHS, may promote cell survival through modulation of caspase activity and may be antiinflammatory through NF-κB inhibition (61). Although we show that CSE has an antiapoptotic effect on PT cells in vitro and others have shown that H2S protects against CKD by reducing apoptosis in murine kidneys (40), there are other mechanisms whereby CSE may be beneficial. CSE, through the generation of cysteine from cystathionine, contributes to the synthesis of the antioxidant glutathione (Figure 8). H2S also inhibits reactive oxygen species (ROS) production by the mitochondria, blocks glucose-induced NADPH oxidase 4, and scavenges ROS (39, 62, 63). Thus, CSE/H2S may be protective in injury through blocking apoptosis, inflammation, or oxidative stress. It was recently reported that FoxO3 is protective in injured renal tubules through effects on autophagy and oxidative stress (64). Although there are likely multiple FoxO3 targets, it may be that FoxO3-dependent cell survival and antioxidant function are mediated, in part, through CSE.

This novel β-catenin/FoxO3/CSE pathway in PTs has important clinical implications for CKD. Because many reports describe the profibrotic actions of β-catenin, particularly in the tubulointerstitium, our data should give pause to blocking this pathway given the beneficial effects on the PT. There have been concerns that sustained β-catenin signaling in the PTs would be detrimental, but our data suggest otherwise and that the location of β-catenin signaling is more important than the duration. Consistent with this, fibroblast-specific β-catenin signaling is detrimental even in AKI (65), a process in which β-catenin signaling is widely considered to be beneficial. Human diabetic nephropathy biopsies show altered β-catenin and FoxO1/3 gene expression profiles, but targeting these transcription factors may be problematic.
given their target-specific actions unless a site-specific approach is feasible (66, 67). Given the beneficial preclinical data on CSE/H$_2$S in CKD (40, 41, 68) and the reduced H$_2$S expression in the plasma of hemodialysis patients (69), this downstream target of Wnt/$\beta$-catenin may have greater therapeutic promise.

Methods

Animal models. Mice with a conditional activating mutation of $\beta$-catenin in which exon 3 of Ctnnb1 is floxed (Ctnnb1$^{ex3fl/fl}$) were produced in-house (Kyoto University) (24). Floxed Foxo3 (Foxo3$^{fl/fl}$) mice were obtained from Jackson Laboratory. Mice expressing Cre recombinase under the control of Ggt promoter (Ggt-Cre) were a gift from Eric Neilson (Vanderbilt University) but are also available at The Jackson Laboratory and have been previously characterized (30). Wnt/$\beta$-catenin reporter or Topflash (Tcf/Lef:H2B-GFP) mice harboring H2B-EGFP fusion protein expression under the control of TCF/LEF1 response element (26) were obtained from The Jackson Laboratory. We used male mice 8–12 weeks old for all injury models. The Ggt-Cre Ctnnb1ex3fl/fl mice were N10 on BALB/c background whereas the other genotypes were on mixed backgrounds.

Injury models. For the AAN model, all mice received intraperitoneal injections of aristolochic acid (AAI, MilliporeSigma) every other day for 2 weeks for a total of 6 injections and were euthanized 6 weeks after the last injection unless stated otherwise. Ggt-Cre Ctnnb1$^{ex3fl}$ and floxed WT mice were given 4.5 mg/kg AA per injection, and Ggt-Cre Ctnnb1$^{ex3fl}$ Foxo3$^{fl/fl}$ mice groups received 6 mg/kg. IRI was carried out as previously described (70). Briefly, mice were anesthetized with ketamine/xylazine and maintained on a 37°C heat pad during surgery. The left kidney was exposed via a flank incision, and the renal pedicle was clamped for 30 minutes. Eight days later, the contralateral kidney was removed, and the mice were sacrificed 4 weeks after the initial unilateral IRI.

Tissue staining and injury score. Kidneys were harvested, fixed in 4% paraformaldehyde, paraffin-embedded, and stained with H&E and TUNEL as previously described (71) or picrosirius red. For quantification of TUNEL staining, 10–15 high-power fields (original magnification, ×400) were taken per sample, and the number of cortical tubules with TUNEL$^+$ nuclei was counted. For picrosirius red, 10 high-power fields of kidney cortex were taken per sample, and quantification of the area staining red was done using ImageJ (NIH). Colleagues in renal pathology scored renal injury from nonoverlapping fields in the cortex (original magnification, ×200) using the following system for renal injury: 0 = no injury, 1 = 1%–20% of area, 2 = 21%–50% of area, 3 = 51%–75% of area, and 4 = >75%. Tubular injury was defined as tubular sloughing, cast formation, dilatation, degeneration, atrophy, or tubulitis. In all cases, the investigator taking the pictures and counting the nuclei or quantifying the staining or histology did so unaware of the animals’ genotypes.
Tissue immunohistochemistry and fluorescence. Paraffin-embedded tissues were rehydrated with decreasing concentrations of ethanol, and antigen target retrieval was performed with 100 mM Tris buffer (pH 10) in a pressure cooker. The antigen/antibody complexes were detected with biotinylated secondary antibody (BA-1000 Vector Laboratories), amplified with ABC Elite peroxidase (Vector Laboratories), and detected by DAB (MilliporeSigma). For immunofluorescence, the antigen retrieval treatments on paraffin-embedded and OCT-embedded frozen tissues were performed using proteinase K (MilliporeSigma) at 37°C and 10 mM citrate buffer (pH 7.2) at 56°C, respectively. Rehydrated tissue sections were incubated with 1:400 LTL with FITC conjugated (Vector Laboratories) in PBS containing Ca²⁺/Mg²⁺ after blocking with 5% BSA. LTL' area was quantified in ×200 fields (5 fields/sample) using ImageJ. Immunofluorescent images were taken with an Olympus BX51, and all others were taken using a Nikon Eclipse E600 microscope.

Renal function. Blood from the tail vein was collected from injured mice at the time of euthanasia, placed in heparinized tubes, and centrifuged and the plasma supernatant used with the Thermo Infinity Urea Reagent to determine BUN levels.

Subcellular fractionation using renal cortices. Nuclear and cytosolic fractionation were performed as previously described (72). Briefly, uninjured renal cortices were grossly dissected and minced in a Petri dish using cold PBS with protease inhibitors (MilliporeSigma), resuspended in ice-cold buffer (250 mM sucrose, 50 mM Tris-HCl pH 7.4, 5 mM MgCl₂, 1 mM DTT, 25 μg/mL spermine, 25 μg/mL spermidine, and protease inhibitors), homogenized, and centrifuged at 800 g for 15 minutes to yield the whole cytosolic fraction (supernatants) and the nuclear fractions (pellets). The pellets were solubilized in 2 M sucrose, 50 mM Tris-HCl pH 7.4, 5 mM MgCl₂, 1 mM DTT, 25 μg/mL spermine, 25 μg/mL spermidine, and protease inhibitors; filtered; and centrifuged in a swing-bucket ultracentrifuge at 80,000 g for 35 minutes. The pellets, pure nuclei, were resuspended in NE buffer (20 mM HEPES pH 7.9, 1.5 mM MgCl₂, 0.5 M NaCl, 0.2 mM EDTA, 20% glycerol, 1% Triton X-100, 1 mM DTT, and protease and phosphatase inhibitors) and centrifuged 30 minutes at 9000 g. The supernatants were saved as soluble nuclear proteins while the pellets, constituted of DNA tightly bound proteins, were resuspended in RIPA buffer.

Subcellular fractionation using PT cells. Nuclear and cytoplasmic cell fractionation were performed as previously described (35). Briefly, PT cells were lysed with a hypotonic lysis buffer (10 mM HEPES pH 7.8, 10 mM KCl, 2 mM MgCl₂, 0.1 mM EDTA, with protease and phosphatase inhibitors), then centrifuged for 2 minutes at 16,000 g to separate the cytoplasmic fraction (supernatant) from the nuclear compartment (pellet). The pellet was then resuspended in a hypertonic buffer (50 mM HEPES pH 7.9, 15 mM MgCl₂, 0.5 M NaCl, plus 1 mL of lentivirus containing the Topflash/luciferase construct and polybrene or the empty vector for 6 hours at 37°C. PT cells were then replaced with complete PT medium with interferon-γ and interferon-γ was removed to induce differentiation. Primary cell cultures were generated as previously described with some modifications (73). Briefly, renal cortices were digested in collagenase I (1 mg/mL) and dispase (1 mg/mL) with DNase, passed through a 70-μm filter to remove glomeruli, washed with complete PT medium, and plated in RPMI 1640 medium (Corning) supplemented with 10% FBS, then reduced to 5% FBS, 1 mM glucose, and supplements listed above for complete PT medium.

Generation of PT cells with Topflash luciferase reporter. PT cells were incubated with complete PT medium plus 1 mL of lentivirus containing the Topflash/luciferase construct and polybrene or the empty vector for 6 hours at 37°C. PT cells were then replaced with complete PT medium with interferon-γ and moved to 33°C. Cells were incubated with 0.5 μg/mL of puromycin to select infected cells for 1 week. Afterward, cells were cultured in complete PT medium. Lentiviral transduction and Topflash activity were confirmed by luciferase assay after stimulating cells with Wnt3a (Time Bioscience).

Cell experiments with AA, H₂O₂ and reagents. PT cells were plated at 30% confluence in complete PT medium containing 20 μM of AA (unless otherwise specified) for 7 days. For some experiments, the GSK-3 inhibitor BIO (MilliporeSigma) or Wnt3a was added at 500 nM and 10 ng/mL, respectively, unless another dose is mentioned, or an equal volume of diluent while being treated with AA. Cells were treated 24 hours with 100 μM H₂O₂ to generate oxidative stress.
siRNA. PT cells were transfected with siRNA targeted to FoxO1, FoxO3, or scramble using Silencer Pre-Designed and Validated sequences from Ambion (siRNA ID s80659, s80621; Thermo Fisher Scientific) or a pool of 2 siRNA duplexes to Cth (CSE) from Santa Cruz Biotechnology (sc-142618). Cells were transfected in OptiMEM using lipofectamine RNAiMax (Thermo Fisher Scientific).

PCR. RNA was extracted from tissue and from cells using the QIAGEN RNeasy Mini Kit, and Bio-Rad’s iScript cDNA Synthesis Kit generated cDNA. For RNA extraction, PT cells were directly lysed with RLT buffer (QIAGEN) while renal cortices were mechanically disrupted in Lysis Matrix Tubes (MP Biomedicals) containing the lysis buffer (RLT) supplemented with 1% β-mercaptoethanol before being purified on the silica membrane RNeasy spin columns. Quantitative real-time PCR was performed with 25–100 ng cDNA and iQ SYBR Green Supermix using the Bio-Rad CFX96 thermal cycler. Relative mRNA expressions were determined by ΔΔCT equation, and, after validation with a panel of housekeeping genes, Gapdh was used as a reference gene. Primer sequences are as follows (forward and reverse): Gapdh 5′-AGGTCGGTTGAACGGATTTG-3′ and 5′-TGTAGACCATGTAGTTGAGGTC-3′; Haver1 (KIM-1) 5′-CTCTAAGCGTGTTGCCCTTC-3′ and 5′-GGGGACTGTACTCATTCT-3′; Colla1 5′-GGGGTCTAGACAGTGTCGTTTGTG-3′ and 5′-ACCCTTAGGCCATTTAGTGATG-3′; Foxo2 5′-TGAGCTGGTTGTACCTACT-3′ and 5′-CAGCCTGCTCGTCCCA-3′; Foxo3 5′-CCAGGGATGGTCAGTTTCT-3′ and 5′-TCATTGATCCCGAGGGTAGC-3′.

RNA-Seq analysis. PT cells were treated with siRNA to Foxo1, Foxo3, Foxo1/3, or scramble; exposed to oxidative stress using 100 μM H2O2 in serum-free medium; and treated with Wnt3a to activate β-catenin. RNA-Seq was performed by the VUMC Core Vanderbilt Technologies for Advanced Genomics using the Illumina HiSeq 2500. Data analysis was performed by the VUMC Core Vanderbilt Technologies for Advanced Genomics Analysis and Research Design, and the RNA-Seq data were quality controlled following the multiperspective guideline (74). Quality control metrics were computed from software QC3 (75), and no quality issues were observed. Alignment was performed by TopHat 2 (76) on MM10 mouse reference genome followed by gene quantification into fragments per kilobase million using Cufflinks (77). Differential expression analyses were performed using cuffdiff from the Cufflinks package. P values were adjusted using the Benjamini-Hochberg method. These data have been uploaded to the National Center for Biotechnology Information’s Gene Expression Omnibus database and can be accessed through record GSE144915.

Immunoblot and reagents. Cells were lysed using MilliporeSigma’s Mammalian Lysis Buffer plus protease and phosphatase inhibitors, sheared using an insulin syringe, clarified by centrifugation, and quantified using the BCA protein assay (Thermo Fisher Scientific). Tissue lysates were generated as described in the subcellular fractionation sections. Both cell and tissue samples were separated by SDS-PAGE and incubated with the following primary antibodies from Cell Signaling Technology: β-catenin (9587S), cleaved caspase-3 (9664S/5A1E), α-tubulin (3873S/DM1A), histone H3 (3638/96C10), and FoxO3 (12829/D19A7); Santa Cruz Biotechnology: nitrotyrosine (sc-32757/39B6) and FAK (sc-558, C-20); Abcam: cystathionase (ab151769); and Vector Laboratories: LTL (FL-1321). ImageJ software was used to quantify bands on autoradiography film.

Nuclear coimmunoprecipitation. Nuclear protein fractions were isolated as described above. Proteins interacting with β-catenin were pulled down using β-catenin antibody (Cell Signaling Technology) or IgG control and protein A agarose beads (Pierce Biotechnology, Thermo Fisher Scientific). After multiple washes in IP buffer (25 mM Tris, 150 mM NaCl; pH 7.2 with protease inhibitors), proteins were eluted, denatured, and probed with FoxO3 antibody.

Statistics. We used the 2-tailed Student’s t test with unequal variance to compare 2 sets of data, with P < 0.05 considered statistically significant. The 1-way ANOVA was used for experiments in which there were multiple comparisons. All experiments subject to analysis were performed at least 3 times. Quantitative data graphs are shown as dot plots with the mean ± SEM.

Study approval. All procedures were approved by the Institutional Animal Care and Use Committee of VUMC and conducted according to the NIH’s Guide for the Care and Use of Laboratory Animals (National Academies Press, 2011).

Author contributions
SNK began the project, which was finished by YO, and both performed experiments in vivo and in vitro and helped in the writing and editing of the manuscript. LS performed the IRI experiments; MPM did all the mouse colony maintenance and genotyping. JT, KSD, SN, AI, TH, and RM performed experiments,
analyzed data, and edited the manuscript. HY did the histologic scoring, and MMT, MD, BK, RCH, and EL helped with key reagents, experimental design, and editing of the manuscript. LSG conceived of the project, oversaw the experiments, and wrote and edited the manuscript.

Acknowledgments

This work was supported by NIH grants R01-DK-108968-01 (LG), DK51265 (RCH), R35GM122516 (EL), 1R01DK112688 (MD), and W81XWH-17-1-0610 (MD); Vanderbilt O’Brien Kidney Center NIH grant 1-P30-DK-114809-01 (LG); Swiss National Science Foundation; Ambizione grant PZ00P3_179916 (SNK); and the Vanderbilt Center for Kidney Disease, Department of Veterans Affairs, Veterans Health Administration VA Merit Awards I01BX003425-01A1 (LG), 00507969 (RCH), and I01BX001340 (BK).

Address correspondence to: Leslie Gewin, Room S3304 MCN, 1161 21st Avenue South, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA. Phone: 615.343.0767; Email: l.gewin@vumc.org.


